MRM Health Reports Positive Topline Results from Phase 2a Clinical Study with MH002 in Mild-to-Moderate Ulcerative Colitis
MRM Health NV, a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics, today reports positive topline results from its Phase 2a clinical trial with MH002 in mild-to-moderate Ulcerative Colitis (UC).
MRM Health’s MH002-UC-201 study was a multi-center, double-blind, randomized, placebo-controlled trial in 45 UC patients at multiple clinical sites in Belgium, Poland and Czech Republic. The study was designed to evaluate safety (primary endpoint), initial efficacy and mechanistic effects of MH002 over eight weeks, with a further eight-week extension period. More information about the trial is available at clinicaltrialsregister.eu.
The primary endpoint was met with an excellent safety profile and tolerance at a fixed dose of 400mg per day over 16 weeks administration. Treatment-Emergent Adverse Events (TEAE) were reported in 35% of patients allocated to MH002 treatment compared to 57% when treated with placebo and there was no evidence of adverse reactions related to MH002.
Initial efficacy on disease activity was evidenced in clinically relevant parameters, including a 12% improvement in Mayo Endoscopic Severity (MES) score (p=0.05, 1-sided Wilcoxon rank sum test), while placebo worsened by 5%. Stool consistency significantly improved in the MH002 treatment group as from week 2 (p=0.006; 1-sided Student t-test). At the end of the eight-week period, 18% of subjects achieved clinical remission compared to 0% of the placebo group (Per-protocol analysis). As opposed to previous trials with other live biotherapeutics in UC, this study was performed successfully without vancomycin preconditioning.
At a mechanistic level, anti-inflammatory effect was demonstrated with 42% decrease in median fecal calprotectin (a clinically relevant bowel inflammation marker) compared to 18% in placebo at week 8.
“These early results indicate that MH002 is safe and well tolerated by patients, and has potential efficacy in mild-to-moderate UC patients who have not responded sufficiently to first-line treatment,” commented Séverine Vermeire, coordinating investigator of study MH002-UC-201 and Professor of Medicine at the KU Leuven, Belgium. “There is a significant absence of treatments for UC patients, particularly in this population, so I look forward to conducting the full analysis of the data and following MH002’s progression through the clinic.”
Bruce Sands, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York and paid consultant to MRM Health, added: “MH002’s mechanism of action and anti-inflammatory effect in UC look very promising, with the potential of a highly favorable benefit/risk balance, pending larger confirmatory studies. These topline results also suggest that this formulation could have applications across a wider range of other inflammatory bowel disorders, including pouchitis, in which MH002 is also being tested.”
Full analysis and presentation of the data is expected by the end of 2023. The Company has initiated to progress the program into Phase 2/3 development.
Ludo Haazen, Chief Medical Officer at MRM Health, added:“This first clinical study enables us to move forward with our clinical programme in UC. We are excited to see that MH002 differentiated in this early study significantly and consistently from placebo in clinically relevant parameters, including the centrally assessed MES, which was supported by the mechanistic parameters we have measured.”
MH002 is currently the most advanced rationally-designed consortium therapy in the UC field. It was developed through MRM Health’s proprietary CORAL® Technology and comprises six well-characterized commensal strains, selected and optimized to tackle key disease-driving mechanisms with enhanced potency, resiliency, and engraftment. Production is via MRM Health’s breakthrough scalable and standardized cGMP manufacturing platform, allowing the manufacturing of complete consortia as a single drug substance. The ability of CORAL® to enable scalable, cost-effective manufacturing of complete optimized consortia in a single process is expected to provide both key regulatory and patient compliance advantages.
In addition to the recently completed UC trial, MH002 is being tested in an ongoing multi-center, open label Phase 2 study enrolling patients with acute Pouchitis, a rare disease with high unmet medical need.
Sam Possemiers, Chief Executive Officer at MRM Health, said: “These early clinical data are very important for the Company, since they further validate our proprietary CORAL® technology which underlies our portfolio of live biotherapeutic products. The data enables us to take the next steps in our business strategy where we will be engaging with regulatory agencies in all territories and potential new partners as well as driving forward the rest of our development portfolio.”
About MRM Health
MRM Health is a clinical-stage biotech developing innovative therapeutics for inflammatory, CNS and metabolic diseases. The Company’s most advanced program MH002 is in preparation for pivotal clinical development in Ulcerative Colitis, upon obtaining positive clinical results in a phase 2a clinical trial, and is being evaluated in the orphan disease indication Pouchitis. MRM Health leverages its proprietary disruptive CORAL® technology platform to design microbiome-based biotherapeutics, based on disease-focused specific combinations of 5 to 10 live gut bacteria, and to optimize them for faster onset-of-action and increased potency and robustness. A significant differentiator is the ability to manufacture these consortia as single drug substance in a single standardized, scalable and highly cost-effective process. In addition to the program in Inflammatory Bowel Diseases, MRM Health has ongoing preclinical programs in Parkinson’s Disease and Spondyloarthritis, and partnered programs with IFF in Type 2 Diabetes and NAFLD.
For more information, please visit the website at www.mrmhealth.com.
About IBD and UC
Ulcerative colitis (UC) is a chronic, autoimmune, inflammatory bowel disease (IBD) characterized by mucosal inflammation of the colon resulting in debilitating diarrhea, abdominal pain, and rectal bleeding with significant impact on quality of life of patients and an increased risk of colorectal cancer development. Whereas many treatments exist and are in development for moderate-to-severe UC, only very limited options are available for mild-to-moderate disease. Current therapies have a merely symptomatic anti-inflammatory and/or an immunosuppressant effect and in many cases fail to induce enduring remission and/or cause potentially severe adverse events. These treatments also do not tackle what is considered as one of the core problems of UC, the overall poverty of microorganisms present in the gut of UC patients, also termed gut dysbiosis. MH002 is designed to enrich the gut microbiome of UC patients and thereby tackle what is considered a root cause of the disease.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For further information please contact:
Dr Sam Possemiers – CEO
Christiane Verhaegen – CFO
Instinctif Partners (media)
Tel: +44 207 457 2020
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Higround and The Pokémon Company International Invite Fans to Explore Fan-Favorite Pokémon in New Collection4.12.2023 22:31:00 CET | Press release
In a new and special collaboration, Higround, a powerhouse within the lifestyle and gaming spheres, is teaming up with The Pokémon Company International to create an exciting collection that seamlessly blends the worlds of competitive gaming, and the beloved Pokémon franchise. This unique partnership introduces a carefully curated collection of gaming peripherals inspired by fan-favorite Pokémon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231204512387/en/ Pokémon + Higround Blastoise Summit 65 Keyboard (Photo: Business Wire) Higround introduces its line of Pokémon-themed keyboards and additional accoutrement, offering fans a tactile way to connect with their favorite franchise. In this unique collection, the Base 65 and Summit 65 Keyboards take center stage. The Base 65 models, for the everyday adventurer, feature designs like the iconic Poké Ball and fan-favorite Pokémon, including Venusaur, Charizard, Blastoise, and Me
Gurobi 11.0 Delivers Global Nonlinear Solving, Speed Enhancements, Dynamic Distributed Tuning, and Enterprise Features4.12.2023 19:48:00 CET | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the release of Gurobi Optimizer 11.0. This advancement marks a significant step forward in solving real-world nonlinear problems with Gurobi. With Gurobi 11.0, users can quickly identify precise, globally optimal solutions to complex nonlinear problems—from domains such as chemical engineering, electricity flow, and price optimization. Additionally, this new version delivers a key enhancement to Gurobi’s popular tuning tool, enabling teams to share resources across multiple users and jobs when tuning. As with every major Gurobi release, users will experience a boost to Gurobi’s industry-leading solver speed. Compared to Gurobi 10.0, version 11.0 delivers the following performance improvements: Algorithm Speed-Up: Overall (>1 sec) Speed-Up: On Hard Models (>100sec) MILP 8.6% 12.4% MIQP 12.8% 22.8% Convex MIQCP 9.2% 18.2% Nonconvex MIQCP 133.4% (2.3x) 480.2% (5.8x) “For nonconvex problems, we achiev
Fitch Group Completes Acquisition of Bixby4.12.2023 19:46:00 CET | Press release
Fitch Group, a global leader in financial information services owned by Hearst, today announced that it has completed the acquisition of all the remaining stock it does not own of Bixby Research and Analytics (“Bixby”), a leading provider of credit information on private syndicated loan issuers. Earlier this year Fitch Ventures, the equity investment arm of Fitch Group, led Bixby’s Series A round. Bixby, founded by Brian Conroy, will become a wholly-owned subsidiary of Fitch Solutions and will be managed by CreditSights. Bixby will be incorporated into CreditSights’ leveraged finance product suite, which includes Covenant Review’s legal analysis, LevFin Insights’ news and data, and CreditSights’ fundamental research. Ted Niedermayer, President of Fitch Solutions, said: “The acquisition of Bixby is a natural next step as we continue to prioritize our leveraged finance offerings. Bixby’s data provides complementary insights to CreditSights, which bolsters our loan offering and also allow
SoftServe Named as a Challenger in 2023 Gartner Magic Quadrant for Custom Software Development Services, Worldwide4.12.2023 18:31:00 CET | Press release
SoftServe, a premier IT consulting and digital services provider, today announced it has been named by Gartner® as a Challenger in the 2023 Magic Quadrant™ for Custom Software Development Services, Worldwide. SoftServe was recognized for its ability to execute and completeness of vision. “SoftServe is recognized throughout the market as a preferred partner for some of the world’s leading technology providers and enterprises,” said Alex Chubay, SoftServe’s CTO. “Our approach involves a holistic perspective encompassing business acumen, user experience, cloud and data engineering, along with cutting-edge technologies – such as Generative AI – that enable our clients to build award-winning digital products and transform their businesses.” Magic Quadrant reports are a culmination of rigorous, fact-based research in specific markets, providing a wide-angle view of the relative positions of the providers in markets where growth is high and provider differentiation is distinct. For more than
Limited Libations, Innovative Blending, Escapism Elixirs and More are Shaping the Way That Consumers Drink in 2024, Based on the Bacardi Cocktail Trends Report4.12.2023 16:40:00 CET | Press release
Bacardi Limited, the world’s largest privately held international spirits company, releases its fifth annual Bacardi Cocktail Trends Report, anticipating the key trends that will redefine cocktail culture and the spirits business in 2024. The report, created in collaboration with strategic foresight consultancy, The Future Laboratory (TFL), draws on insights from Bacardi-led and external research, interviews with bartenders and insights from The Future Laboratory to share the themes that are transforming flavor preferences, drink formats, and cocktail experiences in the coming year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231202332985/en/ Find out what's in store for 2024 with the Bacardi Cocktail Trends Report. (Graphic: Business Wire) “As 2024 arrives, people are looking to settle into the unsettled – welcoming tastes of optimism into our reality. In this landscape, people are reshaping cocktail culture, infusing it